Marshall Wace’s Prelude Therapeutics PRLD Stock Holding History

Marshall Wace’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.02M	Sell	190,692 -168,214	-47%	-$732K	﹤0.01%	2177
2026 Q1	$1.23M	Buy	358,906 +85,023	+31%	+$223K	﹤0.01%	2039
2025 Q4	$794K	Buy	+273,883	New	+$462K	﹤0.01%	2047
2025 Q3	–	Sell	-41,747	Closed	-$33.8K	–	3302
2025 Q2	$33.8K	Buy	+41,747	New	+$36.1K	﹤0.01%	2619
2025 Q1	–	Sell	-392,155	Closed	-$498K	–	3002
2024 Q4	$498K	Buy	392,155 +33,018	+9%	+$43.8K	﹤0.01%	2027
2024 Q3	$743K	Buy	+359,137	New	+$1.66M	﹤0.01%	1771
2022 Q3	–	Sell	-45,716	Closed	-$238K	–	3701
2022 Q2	$238K	Sell	45,716 -66,061	-59%	-$336K	﹤0.01%	3107
2022 Q1	$772K	Sell	111,777 -156,241	-58%	-$1.43M	﹤0.01%	2563
2021 Q4	$3.34M	Buy	+268,018	New	+$4.36M	0.01%	1687
2021 Q2	–	Sell	-29,315	Closed	-$1.27M	–	2994
2021 Q1	$1.27M	Buy	+29,315	New	+$1.94M	0.01%	1538

Other funds holding PRLD

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Marshall Wace's PRLD Position: Q2 2026 in Review

Marshall Wace reduced its Prelude Therapeutics (PRLD) stake by 47% in Q2 2026, selling an estimated $732K and leaving 190,692 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #2177.

Marshall Wace first reported a position in PRLD in Q1 2021 and has held it in 10 quarters since. The position peaked at $3.34M in Q4 2021. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

Marshall Wace held 190,692 shares of Prelude Therapeutics worth $1.02M as of Q2 2026.
Marshall Wace sold 168,214 Prelude Therapeutics shares in Q2 2026, an estimated $732K.
Prelude Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2177 holding.
Marshall Wace first reported a position in Prelude Therapeutics in Q1 2021 and has held it in 10 quarters since.
Marshall Wace's Prelude Therapeutics position peaked at $3.34M in Q4 2021.
75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.